Literature DB >> 30796632

Progress report: familial pancreatic cancer.

Ioannis Mintziras1, Detlef K Bartsch2.   

Abstract

A hereditary predisposition to pancreatic ductal adenocarcinoma (PDAC) is reported in approximately 5% of patients. Familial pancreatic cancer (FPC) accounts for the vast majority of hereditary PDAC cases. FPC defines families with two or more affected first-degree relatives with PDAC that do not fulfil the criteria of any other inherited tumor syndrome or families with PDAC in three or more relatives of any degree. The current progress report focuses on the knowledge of FPC with regard to molecular pathogenesis, clinical and molecular diagnosis, surveillance and novel treatment options reported in the last 5 years.

Entities:  

Keywords:  Familial pancreatic cancer; Molecular pathogenesis; Screening; Treatment

Mesh:

Substances:

Year:  2019        PMID: 30796632     DOI: 10.1007/s10689-019-00125-9

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  28 in total

1.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

Authors:  Bella Kaufman; Ronnie Shapira-Frommer; Rita K Schmutzler; M William Audeh; Michael Friedlander; Judith Balmaña; Gillian Mitchell; Georgeta Fried; Salomon M Stemmer; Ayala Hubert; Ora Rosengarten; Mariana Steiner; Niklas Loman; Karin Bowen; Anitra Fielding; Susan M Domchek
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

2.  A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals.

Authors:  F Harinck; I C A W Konings; I Kluijt; J W Poley; J E van Hooft; H M van Dullemen; C Y Nio; N C Krak; J J Hermans; C M Aalfs; A Wagner; R H Sijmons; K Biermann; C H van Eijck; D J Gouma; M G W Dijkgraaf; P Fockens; M J Bruno
Journal:  Gut       Date:  2015-05-18       Impact factor: 23.059

3.  Limited resection of pancreatic cancer in high-risk patients can result in a second primary.

Authors:  T P Potjer; D K Bartsch; E P Slater; E Matthäi; B A Bonsing; H F A Vasen
Journal:  Gut       Date:  2015-04-02       Impact factor: 23.059

4.  Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.

Authors:  Hans Vasen; Isaura Ibrahim; Carmen Guillen Ponce; Emily P Slater; Elvira Matthäi; Alfredo Carrato; Julie Earl; Kristin Robbers; Anneke M van Mil; Thomas Potjer; Bert A Bonsing; Wouter H de Vos Tot Nederveen Cappel; Wilma Bergman; Martin Wasser; Hans Morreau; Günter Klöppel; Christoph Schicker; Martin Steinkamp; Jens Figiel; Irene Esposito; Evelina Mocci; Enrique Vazquez-Sequeiros; Alfonso Sanjuanbenito; Maria Muñoz-Beltran; José Montans; Peter Langer; Volker Fendrich; Detlef K Bartsch
Journal:  J Clin Oncol       Date:  2016-04-25       Impact factor: 44.544

5.  Variation in precursor lesions of pancreatic cancer among high-risk groups.

Authors:  Thomas P Potjer; Ingrid Schot; Peter Langer; Johannes T Heverhagen; Martin N J M Wasser; Emily P Slater; Günter Klöppel; Hans M Morreau; Bert A Bonsing; Wouter H de Vos Tot Nederveen Cappel; Mathias Bargello; Thomas M Gress; Hans F A Vasen; Detlef K Bartsch
Journal:  Clin Cancer Res       Date:  2012-11-21       Impact factor: 12.531

6.  Multiple small "imaging" branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia?

Authors:  D K Bartsch; K Dietzel; M Bargello; E Matthaei; G Kloeppel; I Esposito; J T Heverhagen; T M Gress; E P Slater; P Langer
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

7.  Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.

Authors:  Nicholas J Roberts; Alexis L Norris; Gloria M Petersen; Melissa L Bondy; Randall Brand; Steven Gallinger; Robert C Kurtz; Sara H Olson; Anil K Rustgi; Ann G Schwartz; Elena Stoffel; Sapna Syngal; George Zogopoulos; Syed Z Ali; Jennifer Axilbund; Kari G Chaffee; Yun-Ching Chen; Michele L Cote; Erica J Childs; Christopher Douville; Fernando S Goes; Joseph M Herman; Christine Iacobuzio-Donahue; Melissa Kramer; Alvin Makohon-Moore; Richard W McCombie; K Wyatt McMahon; Noushin Niknafs; Jennifer Parla; Mehdi Pirooznia; James B Potash; Andrew D Rhim; Alyssa L Smith; Yuxuan Wang; Christopher L Wolfgang; Laura D Wood; Peter P Zandi; Michael Goggins; Rachel Karchin; James R Eshleman; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Ralph H Hruban; Alison P Klein
Journal:  Cancer Discov       Date:  2015-12-09       Impact factor: 39.397

8.  BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.

Authors:  David B Zhen; Kari G Rabe; Steven Gallinger; Sapna Syngal; Ann G Schwartz; Michael G Goggins; Ralph H Hruban; Michele L Cote; Robert R McWilliams; Nicholas J Roberts; Lisa A Cannon-Albright; Donghui Li; Kelsey Moyes; Richard J Wenstrup; Anne-Renee Hartman; Daniela Seminara; Alison P Klein; Gloria M Petersen
Journal:  Genet Med       Date:  2014-11-20       Impact factor: 8.822

9.  The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome.

Authors:  Marcin R Lener; Aniruddh Kashyap; Wojciech Kluźniak; Cezary Cybulski; Agnieszka Soluch; Sandra Pietrzak; Tomasz Huzarski; Jacek Gronwald; Jan Lubiński
Journal:  Cancer Res Treat       Date:  2016-07-28       Impact factor: 4.679

10.  The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic Cancer.

Authors:  Detlef K Bartsch; Norman Gercke; Konstantin Strauch; Ronja Wieboldt; Elvira Matthäi; Vinona Wagner; Susanne Rospleszcz; Agnes Schäfer; Frederike S Franke; Ioannis Mintziras; Christian Bauer; Tobias Grote; Jens Figiel; Pietro Di Fazio; Andreas Burchert; Silke Reinartz; Elke Pogge von Strandmann; Günter Klöppel; Emily P Slater
Journal:  J Clin Med       Date:  2018-09-20       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.